| Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation ND Kauff, JM Satagopan, ME Robson, L Scheuer, M Hensley, CA Hudis, ... New England Journal of Medicine 346 (21), 1609-1615, 2002 | 1680 | 2002 |
| Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia TP Hughes, J Kaeda, S Branford, Z Rudzki, A Hochhaus, ML Hensley, ... New England Journal of Medicine 349 (15), 1423-1432, 2003 | 1604 | 2003 |
| Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for … RG Maki, JK Wathen, SR Patel, DA Priebat, SH Okuno, B Samuels, ... Journal of Clinical Oncology 25 (19), 2755-2763, 2007 | 851 | 2007 |
| Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized … GD Demetri, M Von Mehren, RL Jones, ML Hensley, SM Schuetze, ... Journal of Clinical Oncology 34 (8), 786-793, 2016 | 842 | 2016 |
| Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial ML Hensley, R Maki, E Venkatraman, G Geller, M Lovegren, ... Journal of Clinical Oncology 20 (12), 2824-2831, 2002 | 813 | 2002 |
| What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? DS Chi, EL Eisenhauer, J Lang, J Huh, L Haddad, NR Abu-Rustum, ... Gynecologic oncology 103 (2), 559-564, 2006 | 738 | 2006 |
| American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants ML Hensley, KL Hagerty, T Kewalramani, DM Green, NJ Meropol, ... Journal of clinical oncology 27 (1), 127-145, 2009 | 695 | 2009 |
| Phase II study of sorafenib in patients with metastatic or recurrent sarcomas RG Maki, DR D'Adamo, ML Keohan, M Saulle, SM Schuetze, SD Undevia, ... Journal of Clinical Oncology 27 (19), 3133-3140, 2009 | 662 | 2009 |
| A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies C Aghajanian, S Soignet, DS Dizon, CS Pien, J Adams, PJ Elliott, ... Clinical cancer research 8 (8), 2505-2511, 2002 | 615 | 2002 |
| Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers L Scheuer, N Kauff, M Robson, B Kelly, R Barakat, J Satagopan, N Ellis, ... Journal of Clinical Oncology 20 (5), 1260-1268, 2002 | 556 | 2002 |
| American Society of Clinical Oncology Clinical Practice Guidelinesfor the Use of Chemotherapy and Radiotherapy Protectants ML Hensley, LM Schuchter, C Lindley, NJ Meropol, GI Cohen, G Broder, ... Journal of Clinical Oncology 17 (10), 3333-3355, 1999 | 483 | 1999 |
| Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial ML Hensley, JA Blessing, R Mannel, PG Rose Gynecologic oncology 109 (3), 329-334, 2008 | 376 | 2008 |
| Patient online self-reporting of toxicity symptoms during chemotherapy E Basch, D Artz, D Dulko, K Scher, P Sabbatini, M Hensley, N Mitra, ... Journal of clinIcal oncology 23 (15), 3552-3561, 2005 | 355 | 2005 |
| Identification of prognostic factors in advanced epithelial ovarian carcinoma DS Chi, JB Liao, LF Leon, ES Venkatraman, ML Hensley, D Bhaskaran, ... Gynecologic oncology 82 (3), 532-537, 2001 | 352 | 2001 |
| Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients P Sabbatini, T Tsuji, L Ferran, E Ritter, C Sedrak, K Tuballes, ... Clinical cancer research 18 (23), 6497-6508, 2012 | 326 | 2012 |
| Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging CH Kim, RA Soslow, KJ Park, EL Barber, F Khoury-Collado, JN Barlin, ... International Journal of Gynecologic Cancer 23 (5), 2013 | 290 | 2013 |
| 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology LM Schuchter, ML Hensley, NJ Meropol, EP Winer Journal of Clinical Oncology 20 (12), 2895-2903, 2002 | 277 | 2002 |
| Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study ML Hensley, JA Blessing, K DeGeest, O Abulafia, PG Rose, HD Homesley Gynecologic oncology 109 (3), 323-328, 2008 | 261 | 2008 |
| Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study EA Hahn, GA Glendenning, MV Sorensen, SA Hudgens, BJ Druker, ... Journal of Clinical Oncology 21 (11), 2138-2146, 2003 | 258 | 2003 |
| Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: results of a prospective study ML Hensley, N Ishill, R Soslow, J Larkin, N Abu-Rustum, P Sabbatini, ... Gynecologic oncology 112 (3), 563-567, 2009 | 250 | 2009 |
